Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. (Q34367199)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. |
scientific article |
Statements
1 reference
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. (English)
1 reference
Peter Iversen
1 reference
Jan-Erik Johansson
1 reference
Pär Lodding
1 reference
Olavi Lukkarinen
1 reference
Per Lundmo
1 reference
Peter Klarskov
1 reference
Teuvo L J Tammela
1 reference
Ilker Tasdemir
1 reference
Tom Morris
1 reference
Kevin Carroll
1 reference
Scandinavian Prostatic Cancer Group
1 reference
1 November 2004
1 reference
1 reference
Identifiers
1 reference